Comparative Pharmacology
Head-to-head clinical analysis: HISTAFED versus OPCON A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HISTAFED versus OPCON A.
HISTAFED vs OPCON-A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HISTAFED is a combination of pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa causing vasoconstriction, and triprolidine, a first-generation antihistamine that competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, thereby preventing histamine-mediated effects.
Synthetic vasopressin analog; stimulates V1 receptors on vascular smooth muscle causing vasoconstriction, and V2 receptors in renal collecting ducts increasing water reabsorption.
60 mg orally every 4 to 6 hours as needed; maximum 360 mg per day.
0.1% ophthalmic solution: 1 drop in the affected eye(s) every 3-4 hours as needed for redness relief.
None Documented
None Documented
3-4 hours for pseudoephedrine component; shorter in children (2-3 h), prolonged in renal impairment
Terminal elimination half-life is approximately 2-4 hours in healthy adults; may be prolonged in renal impairment.
Renal (approximately 65% as unchanged drug and metabolites), biliary/fecal (35%)
Primarily renal excretion of unchanged drug and metabolites; about 70-80% of the dose eliminated via urine within 24 hours, with 10-20% fecal elimination.
Category C
Category C
Antihistamine/Decongestant Combination
Ophthalmic Antihistamine/Decongestant Combination